MARKET

RPRX

RPRX

Royalty Pharma Plc
NASDAQ
58.21
-0.08
-0.14%
After Hours: 58.15 -0.06 -0.10% 19:58 09/25 EDT
OPEN
58.50
PREV CLOSE
58.29
HIGH
58.50
LOW
57.68
VOLUME
1.87M
TURNOVER
--
52 WEEK HIGH
64.38
52 WEEK LOW
33.97
MARKET CAP
33.47B
P/E (TTM)
31.00
1D
5D
1M
3M
1Y
5Y
1D
Did AI Expansion Just Shift Royalty Pharma's (RPRX) Investment Narrative?
Simply Wall St · 17h ago
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
The Motley Fool · 1d ago
Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)
TipRanks · 2d ago
Weekly Report: what happened at RPRX last week (0914-0918)?
Weekly Report · 5d ago
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 6d ago
Is Royalty Pharma (RPRX) Below Fair Value After The Pelacarsen Trial Miss?
Simply Wall St · 09/16 02:21
Weekly Report: what happened at RPRX last week (0907-0911)?
Weekly Report · 09/14 09:56
Royalty Pharma to present at upcoming investor conferences
Barchart · 09/09 15:05
More
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.

Webull offers Royalty Pharma plc stock information, including NASDAQ: RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.